Preview Mode Links will not work in preview mode

Jun 5, 2018

Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds. We are on the cusp of having previously unimaginable amounts of information about each target and many more targets to prosecute.

Thanks to more frequent co-operative hit discovery programmes, the need for increased screening capacity is pronounced. As we learn so much more about targets, drug discovery scientists must have access not only to more screening but also to smarter screening.

At AstraZeneca, this situation drove them to make a significant investment in rethinking their approach to compound screening – everything from where those compounds are stored to how rapidly they can be accessed and assayed.

This article was written by Dr Clive Green and Dr Philip Spencer, of Astrazeneca

If you'd like to view the original article then follow the link below:

You can also download the original article pdf here:

For more information on Drug Discovery World, head to: